RA Drug Does Not Alter Cholesterol Ratio

APRIL 01, 2005

Patients taking Remicade (infliximab) for rheumatoid arthritis (RA) showed not only an improvement in their condition but also a dramatic increase in both high-density lipoprotein (HDL; "good") cholesterol and total cholesterol. Researcher Michael T. Nurmohamed, MD, noted that, "contrary to expectations,"these changes do not positively alter the ratio between total cholesterol and HDL cholesterol, referred to as the atherogenic index. "Hence, the favorable effect of infliximab on the cardiovascular risk in patients with rheumatoid arthritis is not mediated through modification of the lipid profile,"said Dr. Nurmohamed.

For the study, the researchers examined 69 patients with RA to determine the short-term effects of infliximab on cholesterol levels. The results of the study showed that total cholesterol rose from 5.2 to 5.6 units after 6 weeks, while HDL cholesterol increased from 1.4 to 1.6. (The findings were published in the Journal of Rheumatology, February 2005.)



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.